Classification Term: 3345

N-benzylbenzamides (ontology term: CHEMONTID:0003469)

Compounds containing a benzamide moiety that is N-linked to a benzyl group." []

found 9 associated metabolites at family metabolite taxonomy ontology rank level.

Child Taxonomies: There is no child term of current ontology term.

Trimethobenzamide

N-({4-[2-(dimethylamino)ethoxy]phenyl}methyl)-3,4,5-trimethoxybenzamide

C21H28N2O5 (388.1998118)

Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against emesis induced by intragastric copper sulfate. R - Respiratory system > R06 - Antihistamines for systemic use > R06A - Antihistamines for systemic use > R06AA - Aminoalkyl ethers D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents C78272 - Agent Affecting Nervous System > C267 - Antiemetic Agent D005765 - Gastrointestinal Agents > D000932 - Antiemetics D002491 - Central Nervous System Agents

6a, 3'-p-Dihydroxypaclitaxel

4,12-bis(acetyloxy)-1,8,9,17,17-pentahydroxy-15-{[2-hydroxy-3-(4-hydroxyphenyl)-3-(phenylformamido)propanoyl]oxy}-10,14-dimethyl-11-oxo-6-oxatetracyclo[11.3.1.0³,¹⁰.0⁴,⁷]heptadec-13-en-2-yl benzoate

C45H47NO18 (889.2793002000001)

6a, 3-p-Dihydroxypaclitaxel is a metabolite of paclitaxel. Paclitaxel is a mitotic inhibitor used in cancer chemotherapy. It was discovered in a U.S. National Cancer Institute program at the Research Triangle Institute in 1967 when Monroe E. Wall and Mansukh C. Wani isolated it from the bark of the Pacific yew tree, Taxus brevifolia and named it taxol. When it was developed commercially by Bristol-Myers Squibb (BMS) the generic name was changed to paclitaxel and the BMS compound is sold under the trademark Taxol. (Wikipedia)

5-(2,4-Dioxo-thiazolidin-5-ylmethyl)-2-methoxy-N-(4-trifluoromethyl-benzyl)-benzamide(KRP297)

5-[(4-hydroxy-2-oxo-2,3-dihydro-1,3-thiazol-5-yl)methyl]-2-methoxy-N-{[4-(trifluoromethyl)phenyl]methyl}benzamide

C20H17F3N2O4S (438.08610780000004)

N-[(S)-[1-(Dimethylamino)cyclopentyl](phenyl)methyl]-2,6-dimethylbenzamide

C23H30N2O (350.235801)

Itopride

N-({4-[2-(dimethylamino)ethoxy]phenyl}methyl)-3,4-dimethoxybenzene-1-carboximidate

C20H26N2O4 (358.18924760000004)

A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03F - Propulsives > A03FA - Propulsives C471 - Enzyme Inhibitor > C47792 - Acetylcholinesterase Inhibitor

Sirtinol is a sirtuin (SIRT) inhibitor, with IC50s of 48 μM, 57.7 μM and 131 μM for ySir2, hSIRT2 and hSIRT2, respectively[1][2][3][4].

(2S)-2-((3-((4-(4-Fluorophenoxy)phenyl)methylcarbamoyl)-4-methoxy-phenyl)methyl)butanoic acid

2-{[3-({[4-(4-fluorophenoxy)phenyl]methyl}-C-hydroxycarbonimidoyl)-4-methoxyphenyl]methyl}butanoate

C26H26FNO5 (451.17949180000005)